| Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration RM Perciavalle, DP Stewart, B Koss, J Lynch, S Milasta, M Bathina, ... Nature cell biology 14 (6), 575-583, 2012 | 460 | 2012 |
| Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction X Wang, M Bathina, J Lynch, B Koss, C Calabrese, S Frase, JD Schuetz, ... Genes & development 27 (12), 1351-1364, 2013 | 260 | 2013 |
| A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival NA Cohen, ML Stewart, E Gavathiotis, JL Tepper, SR Bruekner, B Koss, ... Chemistry & biology 19 (9), 1175-1186, 2012 | 164 | 2012 |
| Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways JM Haverkamp, AM Smith, R Weinlich, CP Dillon, JE Qualls, G Neale, ... Immunity 41 (6), 947-959, 2014 | 161 | 2014 |
| Ubiquitin-independent degradation of antiapoptotic MCL-1 DP Stewart, B Koss, M Bathina, RM Perciavalle, K Bisanz, JT Opferman Molecular and cellular biology 30 (12), 3099-3110, 2010 | 145 | 2010 |
| Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia B Koss, J Morrison, RM Perciavalle, H Singh, JE Rehg, RT Williams, ... Blood, The Journal of the American Society of Hematology 122 (9), 1587-1598, 2013 | 94 | 2013 |
| Indicators of responsiveness to immune checkpoint inhibitors BD Shields, F Mahmoud, EM Taylor, SD Byrum, D Sengupta, B Koss, ... Scientific reports 7 (1), 807, 2017 | 88 | 2017 |
| PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation Z Ren, JH Ahn, H Liu, YH Tsai, NV Bhanu, B Koss, DF Allison, A Ma, ... Blood, The Journal of the American Society of Hematology 134 (14), 1176-1189, 2019 | 63 | 2019 |
| Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors T Lee, Z Bian, B Zhao, LJ Hogdal, JL Sensintaffar, CM Goodwin, J Belmar, ... FEBS letters 591 (1), 240-251, 2017 | 63 | 2017 |
| Loss of E-cadherin inhibits CD103 antitumor activity and reduces checkpoint blockade responsiveness in melanoma BD Shields, B Koss, EM Taylor, AJ Storey, KL West, SD Byrum, ... Cancer research 79 (6), 1113-1123, 2019 | 58 | 2019 |
| Mcl-1 antagonizes Bax/Bak to promote effector CD4+ and CD8+ T-cell responses P Tripathi, B Koss, JT Opferman, DA Hildeman Cell Death & Differentiation 20 (8), 998-1007, 2013 | 56 | 2013 |
| Discovery of potent myeloid cell leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer T Lee, PP Christov, S Shaw, JC Tarr, B Zhao, N Veerasamy, KO Jeon, ... Journal of medicinal chemistry 62 (8), 3971-3988, 2019 | 47 | 2019 |
| Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines B Koss, J Ryan, A Budhraja, K Szarama, X Yang, M Bathina, MH Cardone, ... Oncotarget 7 (10), 11500, 2016 | 36 | 2016 |
| CAR-T therapies in solid tumors: opportunities and challenges G Guzman, MR Reed, K Bielamowicz, B Koss, A Rodriguez Current Oncology Reports 25 (5), 479-489, 2023 | 24 | 2023 |
| Epigenetic control of Cdkn2a. Arf protects tumor-infiltrating lymphocytes from metabolic exhaustion B Koss, BD Shields, EM Taylor, AJ Storey, SD Byrum, AJ Gies, ... Cancer Research 80 (21), 4707-4719, 2020 | 23 | 2020 |
| Delivery of phosphatidylethanolamine blunts stress in hepatoma cells exposed to elevated palmitate by targeting the endoplasmic reticulum M Trentzsch, E Nyamugenda, TK Miles, H Griffin, S Russell, B Koss, ... Cell death discovery 6 (1), 8, 2020 | 13 | 2020 |
| Effect of sulforaphane and 5-aza-2’-deoxycytidine on melanoma cell growth T Chiang, B Koss, LJ Su, CL Washam, SD Byrum, A Storey, AJ Tackett Medicines 6 (3), 71, 2019 | 11 | 2019 |
| Histone Modifications as Biomarkers for Immunotherapy EM Taylor, B Koss, LE Davis, AJ Tackett Biomarkers for Immunotherapy of Cancer, 213-228, 2020 | 10 | 2020 |
| Proteomic signatures of innate immunity in immunotherapy naïve melanomas correlate with anti-CTLA-4 immunotherapy responsiveness EM Taylor, B Koss, CL Washam, SC Shalin, JC Barreto, S Graw, ... | 2 | 2020 |
| Chemical inhibition of DNA‐PKcs impairs the activation and cytotoxicity of CD4+ helper and CD8+ effector T cells AC Azevedo‐Pouly, LE Appell, L Burdine, LJ Rogers, LC Morehead, D Fil, ... Immunology and Cell Biology 101 (7), 663-671, 2023 | 1 | 2023 |
